Premium
Dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis
Author(s) -
Maki Nobuki,
Nishie Wataru,
Takazawa Maya,
Kakurai Maki,
Yamada Tomoko,
Umemoto Naoka,
Kawase Masaaki,
Izumi Kentaro,
Shimizu Hiroshi,
Demitsu Toshio
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14254
Subject(s) - bullous pemphigoid , medicine , dipeptidyl peptidase 4 inhibitor , etiology , dipeptidyl peptidase 4 , pemphigoid , dermatology , dipeptidyl peptidase , diabetes mellitus , immunology , pathology , type 2 diabetes mellitus , endocrinology , type 2 diabetes , enzyme , antibody , biology , biochemistry
Bullous pemphigoid ( BP ) is a common autoimmune blistering disorder with unknown etiology. Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase‐4 inhibitors ( DPP 4i), widely used antihyperglycemic drugs, have been reported in published works. Here, we report a case of DPP 4i (teneligliptin)‐associated BP that developed in a 70‐year‐old Japanese man. Interestingly, the patient had acquired reactive perforating collagenosis ( ARPC ), which is also known to be associated with the onset of BP . In the present case, clinical, histopathological and immunological findings suggested that DPP 4i rather than ARPC was associated with the onset of BP .